Cytotoxic drug therapy
KD Bagshawe - US Patent 6,299,876, 2001 - Google Patents
Jodrell, DI, et al.,“The renal effects of N1O—propargyl—5, 8—dideaZafolic acid (CB3717)
and a non—nephrotoxic ana logue ICI D1694, in mice,” Br. J. Cancer; 64: 833—38 (1991) …
and a non—nephrotoxic ana logue ICI D1694, in mice,” Br. J. Cancer; 64: 833—38 (1991) …
Human monocyte-mediated cytotoxicity towards erythrocytes induced by hybrid mouse monoclonal antibodies: effect of antibody binding valency on IgG-Fc gamma R …
P Koolwijk, JG Van de Winkel, I Otten, BJ Bast - Immunology, 1992 - ncbi.nlm.nih.gov
In this study, we describe the ability of hybrid mouse monoclonal antibody (mAb) to induce
monocyte-mediated cytotoxicity towards human IgA1-coated E (HuIgA1-E), and the effect of …
monocyte-mediated cytotoxicity towards human IgA1-coated E (HuIgA1-E), and the effect of …
Cytotoxic drug therapy
KD Bagshawe - US Patent 6,015,556, 2000 - Google Patents
US6015556A - Cytotoxic drug therapy - Google Patents US6015556A - Cytotoxic drug therapy
- Google Patents Cytotoxic drug therapy Download PDF Info Publication number US6015556A …
- Google Patents Cytotoxic drug therapy Download PDF Info Publication number US6015556A …
The current status of tumor targeting: a review
T Ghose - Tumor Targeting in Cancer Therapy, 2002 - Springer
The ultimate goal of cancer therapy is to develop agents that will selectively destroy cancer
cells, sparing the normal tissues of the patient. Unfortunately, most of the currently available …
cells, sparing the normal tissues of the patient. Unfortunately, most of the currently available …
Antibody-mediated cancer diagnosis and therapy
JM Bator, CL Reading - Therapeutic monoclonal antibodies, 1991 - Springer
The development of monoclonal antibodies (Kohler and Milstein, 1975) marked the
beginning of a new era in the diagnosis and treatment of cancer. It has been the goal of …
beginning of a new era in the diagnosis and treatment of cancer. It has been the goal of …
Redirection of cellular cytotoxicity: A two-step approach using recombinant single-chain Fv molecules
AJT George, JA Titus, CR Jost, I Kurucz, P Perez… - Cell biophysics, 1995 - Springer
In this article the authors discuss an indirect system for redirecting cellular cytotoxicity, which
utilizes a “universal” bispecific antibody to redirect T-cells to kill cells targeted with single …
utilizes a “universal” bispecific antibody to redirect T-cells to kill cells targeted with single …
CHEMERA RECEPTOR RECOGNIZING AN ANTIBODY MODIFICATION SITE
M Sakurai, T Igawa, K Tamada, Y SAKODA - 2023 - Google Patents
C07K16/2809—Immunoglobulins [IGs], eg monoclonal or polyclonal antibodies against
material from animals or humans against receptors, cell surface antigens or cell surface …
material from animals or humans against receptors, cell surface antigens or cell surface …
[PDF][PDF] ENGINEERING ANTIBODIES FOR HUMAN THERAPY
EA PADLAN - nast.dost.gov.ph
Antibodies have many polential uses in industry and medicine. Through protein
engineering, the structure of an antibody can be allered and 1he molecule made more …
engineering, the structure of an antibody can be allered and 1he molecule made more …
[PDF][PDF] Wykorzystanie przeciwciał monoklonalnych do celów terapeutycznych
M Kurpisz - Biotechnologia, 1993 - rcin.org.pl
O d chwili uzyskania przez Kohlera i Milsteina (1) pierwszych przeciwciał monokionainych
minęło ponad 15 łat; dokonał się olbrzymi postęp w na ukach med}^ cznych, a szczególnie …
minęło ponad 15 łat; dokonał się olbrzymi postęp w na ukach med}^ cznych, a szczególnie …
Bispecific monoclonal antibodies
S Songsivilai, PJ Lachmann - Monoclonal Antibodies, 1995 - books.google.com
Direct coupling of antibodies to effector compounds, however, has some major
disadvantages. The efficiency of immunoconjugates may be decreased as a result of the …
disadvantages. The efficiency of immunoconjugates may be decreased as a result of the …